Apollo Hospitals: A Robust Q3 FY26 Driven by Integrated Healthcare Ecosystem

Apollo Hospitals Enterprise Limited, a titan in India's healthcare sector, has reported a strong financial performance for the third quarter of fiscal year 2026 (Q3 FY26), ending December 31, 2025. The company demonstrated impressive growth across its diversified business verticals, reinforcing its position as a leading integrated healthcare provider. This quarter's results highlight Apollo's strategic focus on expanding its physical and digital footprint, enhancing clinical excellence, and optimizing operational efficiencies.

On a consolidated basis, Apollo Hospitals recorded a substantial 17% year-on-year (YoY) growth in revenue, reaching INR 6,477 crore. This robust top-line performance translated into a significant 27% YoY increase in EBITDA, which stood at INR 965 crore. The company's profitability also saw a healthy surge, with reported Profit After Tax (PAT) growing by 35% YoY to INR 502 crore. These figures underscore a sustained positive momentum from the first half of the year, indicating the resilience and scalability of Apollo's integrated model.

Segmental Performance: A Balanced Growth Story

The growth was well-distributed across Apollo's key segments:

Healthcare Services: The core hospital business delivered a commendable performance, with revenues growing 14% YoY to INR 3,183 crore. This growth was attributed to a balanced mix of factors: 5% from volume growth, 4% from case mix improvement, and 5% from pricing adjustments. Surgical volumes saw a 6% increase, with CONGO-T (Cardiac, Oncology, Neurosciences, Gastroenterology, Orthopedics, and Transplant) specialties driving a robust 16% YoY revenue growth. The group-wide occupancy rate stood at 67%, and the average revenue per inpatient (ARPP) increased by 11% to INR 180,917, reflecting a higher clinical intensity. EBITDA for this segment grew 18% to INR 719 crore, maintaining strong margins at 24.8%.

Apollo HealthCo (Digital Health & Pharmacy Distribution): This segment reported revenues of INR 2,827 crore, marking a 20% YoY growth. The platform GMV for Apollo 24/7 reached INR 525 crore in Q3 FY26, a 28% increase over the previous year. The digital platform added 2 million new users, expanding its base to over 46 million. The offline pharmacy distribution network grew to 7,113 operating stores, with 185 net new stores opened during the quarter. While the overall GMV saw a sequential moderation due to the impact of GST reduction on pharmacy products and the closure of the Amazon e-commerce channel, the online pharmacy business itself grew by 32%. The segment's EBITDA was INR 1,279 crore, with margins at 4.5%, and it achieved its lowest cash losses in the digital business at INR 29 crore.

Apollo Health & Lifestyle Limited (AHLL - Diagnostics & Retail Health): AHLL continued its strong trajectory, with revenues increasing 20% YoY to INR 467 crore. The segment's EBITDA grew an impressive 39% YoY to INR 48 crore, with margins improving to 10.2% from 8.8% in the prior year. This growth was fueled by the expansion of its diagnostics network, adding 12 satellite labs and 239 collection centers. The wellness segment grew by approximately 32% YoY, contributing about 18% to diagnostics revenue. The newly launched Central Reference Lab (CRL) processed 5.6 million tests, demonstrating a 40% increase in retail volumes and achieving NABL accreditation for over 600 tests.

Strategic Initiatives and Future Outlook

Apollo Hospitals is actively pursuing strategic expansion plans to further strengthen its market leadership. The company operationalized 75 beds in its Pune facility and 30 beds in Defence Colony during Q3 FY26. Looking ahead, it plans to commission four new hospitals in Hyderabad, Kolkata, Bangalore, and Gurgaon in the next fiscal year, adding approximately 1,500 operating beds. This phased commissioning approach aims to optimize capital deployment and drive occupancy-led operating leverage.

The company is also progressing with its Composite Scheme for Apollo HealthCo, which involves the demerger of its omnichannel pharmacy distribution and Apollo 24/7 digital platform, along with the amalgamation of Apollo Healthco Ltd and Keimed Private Limited into a new entity. This new entity is expected to become an 'Indian Owned and Controlled Company' (IOCC) and will apply for listing on stock exchanges, with an estimated listing by Q4 FY27. Management anticipates this combined entity to achieve a run rate of INR 25,000 crore in combined revenues with 7% EBITDA by Q4 FY27.

Despite the strong performance, management acknowledged some challenges, including an estimated INR 150 crore cost headwind for the next year due to new hospital ramp-ups and a one-quarter delay in the digital business's cash EBITDA breakeven to Q1 FY27, primarily due to an insurance mismatch. However, the company remains confident in its ability to mitigate these impacts through operational excellence, asset utilization, and cost optimization.

Conclusion: Sustained Momentum and Strategic Clarity

Apollo Hospitals' Q3 FY26 results reflect the fundamental strength and clinical depth of its integrated care model. The company's disciplined execution, sustained investments in clinical excellence and technology, and proactive market share gains are driving its momentum. With a clear strategy for capacity expansion, digital penetration, and operational efficiency, Apollo Hospitals is well-positioned to continue delivering consistent performance and creating enduring value for its stakeholders in the evolving Indian healthcare landscape.